Summit Therapeutics announces availability of ivonescimab HARMONi trial update press release

Summit Therapeutics Inc

Summit Therapeutics Inc

SMMT

0.00
  • Summit Therapeutics posted an updated overall survival analysis from the Phase III HARMONi study of ivonescimab with platinum-doublet chemotherapy.
  • June 2026 data cut showed an OS hazard ratio of 0.76 in the intention-to-treat population; April 2025 primary OS analysis HR was 0.79.
  • FDA review of the ivonescimab BLA targets a PDUFA action date of Nov. 14, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260722390898) on July 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.